Work

CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response

Year: 2019

Type: article

Source: Cancer Cell

DOI: 10.1016/j.ccell.2019.02.006

Authors: Nicholas F. Kuhn, Terence J. Purdon, Dayenne G. van Leeuwen, Andrea V. Lopez, Kevin J. Curran, Anthony F. Daniyan, Renier J. Brentjens

Institutions: Memorial Sloan Kettering Cancer Center, Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Leukemia and Lymphoma Society, Cabot Family Charitable Trust, Emerald Foundation, National Institutes of Health, National Cancer Institute

Awards: CD40L-Modified Chimeric Antigen Receptor (CAR) T Cells, G3830705226, Adoptive Immunotherapy of Cancer with IL-12 Secreting Tumor-Targeted T cells, G4199952276, Immunologic Approaches to Ovarian Cancer, G5934740974, MSK SPORE in Lymphoma, Genetic Approaches to Cancer Immunotherapy, G9000213381, G9000304259, Cancer Center Support Grant, MSK Paul Calabresi Career Development Award for Clinical Oncology

OpenAlex ID: W2922068441

FWCI: 12.21

Cites: 61

Cited by: 245

Related to: 10